1. Home
  2. CPBI vs CRDF Comparison

CPBI vs CRDF Comparison

Compare CPBI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Central Plains Bancshares Inc.

CPBI

Central Plains Bancshares Inc.

HOLD

Current Price

$20.00

Market Cap

83.2M

Sector

N/A

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.14

Market Cap

86.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPBI
CRDF
Founded
2023
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.2M
86.8M
IPO Year
2023
2012

Fundamental Metrics

Financial Performance
Metric
CPBI
CRDF
Price
$20.00
$1.14
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $5.81
AVG Volume (30 Days)
4.8K
★ 808.3K
Earning Date
11-18-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
9.38
★ 27.37
EPS
★ 0.39
N/A
Revenue
N/A
★ $365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8.70
P/E Ratio
$51.26
★ N/A
Revenue Growth
N/A
★ 49.61
52 Week Low
$15.56
$0.76
52 Week High
$21.83
$3.31

Technical Indicators

Market Signals
Indicator
CPBI
CRDF
Relative Strength Index (RSI) 49.49 45.34
Support Level $19.73 $0.88
Resistance Level $20.74 $1.47
Average True Range (ATR) 0.23 0.08
MACD -0.09 -0.03
Stochastic Oscillator 43.10 10.84

Price Performance

Historical Comparison
CPBI
CRDF

About CPBI Central Plains Bancshares Inc.

Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans. The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans. The company's revenue is derived from the business of banking.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: